To test an investigational cell therapy to see if it is safe for use in patients with Type 1 Diabetes (T1D) and to see if T1D improves after taking it. The investigational cell therapy would be manufactured from your own blood cells and is intended to help correct an imbalance of certain types of cells found in patients with T1D. Correcting this imbalance may help slow down the worsening of T1D.
You will be asked to meet with members of the study team and answer questions about your health and medications. If you are assigned to a specific cohort of the study group, you will be asked to take rapamycin as instructed and keep track of the doses you take in an eDiary. This study involves a leukapheresis procedure and an infusion. It also involves a mixed-meal tolerance test, ECG, blood draws, and CGM use.
Information provided upon request, Treatment with the investigational cell therapy product and, if in a specific cohort, rapamycin
Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA
UNC Eastowne Medical Office Building
100 Eastowne Dr, Chapel Hill, NC 27514, USA
John Buse
Medicine-Endocrinology
Clinical or Medical
Interventional
Diabetes
25-1241
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
